Drug
XEN1101 clinical trials
Also written XEN1101 and Azetukalner.
- studies test it
- 12
- open now
- 3
- in phase 3
- 9
- first study started
- 2019
Keep track of what changes. Save the XEN1101 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
12 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 1
Xenon Pharmaceuticals Inc. (11) · James Murrough (1)
Studies
Open first, then newest update. How each study uses XEN1101 is read from its arms, and is right about nine times in ten.
Testing it · 12
- An Open-label Study of XEN1101 in EpilepsyEnrolling by invitationPhase 3Xenon Pharmaceuticals Inc.NCT05718817Written as XEN1101
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)RecruitingPhase 3Xenon Pharmaceuticals Inc.NCT05716100Written as XEN1101
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresRecruitingPhase 3Xenon Pharmaceuticals Inc.NCT05667142Written as XEN1101
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)Active, not recruitingPhase 3Xenon Pharmaceuticals Inc.NCT07076407Written as Azetukalner
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderActive, not recruitingPhase 3Xenon Pharmaceuticals Inc.NCT06775379Written as Azetukalner
- An Open-Label Study of Azetukalner in Major Depressive DisorderActive, not recruitingPhase 3Xenon Pharmaceuticals Inc.NCT06922110Written as Azetukalner
- An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)Active, not recruitingPhase 3Xenon Pharmaceuticals Inc.NCT07217860Written as Azetukalner
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)Active, not recruitingPhase 3Xenon Pharmaceuticals Inc.NCT07172516Written as Azetukalner
- A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive DisorderCompletedPhase 2Xenon Pharmaceuticals Inc.NCT05376150Written as XEN1101 10 mg
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresCompletedPhase 3Xenon Pharmaceuticals Inc.NCT05614063Written as XEN1101
- XEN1101 for Major Depressive DisorderCompletedPhase 2James MurroughNCT04827901Written as XEN1101
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal EpilepsyActive, not recruitingPhase 2Xenon Pharmaceuticals Inc.NCT03796962Written as XEN1101
Codes
What other systems call XEN1101 · ClinicalTrials.gg INT001423
- MeSH (NLM) C000710655XEN1101One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710655 | XEN1101 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.